In transgenic APP/PS1 mice, deficits in social and objective recognition memory have been developed, similar to the facial recognition impairments observed in patients with AD, and chronic CBD treatment from the early symptomatic stage neutralized these cognitive deficits without any changes in anxiety and associative memory at 7–10 months of age [26,64,93,94]. The gene discussed is APP; the disease is Cognitive impairment.